Preventive effects of bone marrow-derived mesenchymal stem cell transplantation in a D-galactose-induced brain aging in rats

Abstract

Aging is a complex process accompanied by numerous morphological, functional, and metabolic impairments in the brain, and a critical risk factor involved in the increasing incidence of neurodegenerative diseases. Few studies have evaluated the efficacy of different sources of mesenchymal stem cells (MSCs) in ameliorating the early morphological and functional alterations in the aging brain. This study, for the first time, evaluated the potential efficacy of intravenous injection of bone marrow-derived mesenchymal stem cells (BMMSCs) in a D-galactose-induced rat model of brain aging.BMMSCs (1 × 10 6 ) were intravenously injected into brain aging model rats once every two weeks for 8 weeks. The transplanted cells survived and migrated to the brain, and differentiated into astrocytes and neurons, including choline acetyltransferase neurons.BMMSC transplantation improved locomotor activity and cognitive functions, restored cholinergic system function, protected atrophic cholinergic neurons in the basal forebrain, induced antioxidative effects and restored neurotrophic factors, and modulated 1 hippocampal synaptic plasticity by upregulating PSD95 and Egr1 expression. Our findings demonstrated the efficacy of BMMSC injection in an aging rat model and suggest that these cells may be developed into an effective cell therapy for the aging brain.

Transplantation of bone marrow-derived mesenchymal stem cells ameliorated dopamine system impairment in a D-galactose-induced brain ageing in rats

“…Several studies have shown that the DA system, both structurally and functionally, is affected during normal ageing [1][2][3][4][5][6][7][8]. The capability of stem cells to replace lost or malfunctioning cells has been the focus of recent research [36][37][38][39][40][41][42]. This study is the first to examine the potential beneficial effects of systemic transplantation of BMMSCs on the DA system in a D-gal-induced rat model of brain ageing.…”

“…It is possible that early intervention to address neuropathological changes during primary ageing will stop or at least delay the pathological processes leading to secondary ageing, thus lowering the prevalence of agerelated disorders [19][20][21][33][34][35]. Few studies have evaluated the efficacy of MSC transplantation in animal models of ageing [36][37][38][39][40][41][42]. Therefore, we aimed to evaluate, for the first time, the potential beneficial effects of systemic transplantation of BMMSCs on the nigrostriatal system in a D-galactose (D-gal)-induced rat model of brain ageing to evaluate their potential as a protective approach for age-related neurodegeneration.…”